Current status of clopidogrel pharmacogenomics

Pharmacogenomics

Volumn 13, Issue 15, 2012, Pages 1671-1673

  Giusti, Betti ^a   Gori, Anna Maria ^a,b   Marcucci, Rossella ^a   Abbate, Rosanna ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

acute coronary syndrome; antiaggregant; bioinformatics; clopidogrel; genetic testing; pharmacogenetics; pharmacogenomics; predictive algorithms

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C19; ILOPROST; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ACUTE CORONARY SYNDROME; AMINO ACID SUBSTITUTION; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CYP2C19 GENE; DISEASE ASSOCIATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RESPONSE; EXON; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART INFARCTION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; STOP CODON; THROMBOCYTE AGGREGATION;

ACUTE CORONARY SYNDROME; ARYL HYDROCARBON HYDROXYLASES; HUMANS; PHARMACOGENETICS; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; TICLOPIDINE;

EID: 84870002919     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.153     Document Type: Review

References (22)

1. Bonello L, Tantry US, Marcucci R et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919-933 (2010).
2. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel nonresponsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb. Haemost. 103(4), 841-848 (2010).
3. Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306(11), 1215-1223 (2011).
4. Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R. Determinants to optimize response to clopidogrel in acute coronary syndrome. Pharmacogenom. Person. Med. 3, 33-50 (2010).
5. Krishna V, Diamond GA, Kaul S. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: the role of platelet reactivity and genotype testing in the prevention of atherothrombotic cardiovascular events remains unproven. Circulation 125(10), 1288-1303 (2012).
6. Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 125(10), 1276-1287 (2012).
7. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007). (Pubitemid 350106708)
8. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
9. Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17, 1057-1064 (2007). (Pubitemid 351339490)
10. Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363(18), 1704-1714 (2010).
11. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P4502C19 2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J. 11(3), 199-206 (2011).
12. Hulot JS, Collet JP, Silvain J et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C192 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J. Am. Coll. Cardiol. 56(2), 134-143 (2010).
13. Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821-1830 (2010).
14. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA 306(24), 2704-2714 (2011).
15. Sibbing D, Koch W, Gebhard D et al. Cytochrome 2C19 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 121(4), 512-518 (2010).
16. Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010).
17. Wallentin L, James S, Storey RF et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 376(9749), 1320-1328 (2010).
18. Bouman HJ, Schömig E, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17(1), 110-116 (2011).
19. Cayla G, Hulot JS, O'Connor SA et al. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA 306(16), 1765-1774 (2011).
20. Roberts JD, Wells GA, Le May MR et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379(9827), 1705-1711 (2012).
21. Campo G, Parrinello G, Ferraresi P et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57(25), 2474-2483 (2011).
22. Saracini C, Vestrini A, Galora S, Armillis A, Abbate R, Giusti B. Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing. Genet. Test. Mol. Biomarkers 16(6), 500-503 (2012).